DK0536282T3 - Fremgangsmåde til behandling af prostataadenocarcinom hos mennesker - Google Patents

Fremgangsmåde til behandling af prostataadenocarcinom hos mennesker

Info

Publication number
DK0536282T3
DK0536282T3 DK91912759.7T DK91912759T DK0536282T3 DK 0536282 T3 DK0536282 T3 DK 0536282T3 DK 91912759 T DK91912759 T DK 91912759T DK 0536282 T3 DK0536282 T3 DK 0536282T3
Authority
DK
Denmark
Prior art keywords
humans
treating prostate
prostate adenocarcinoma
alpha
reductase inhibiting
Prior art date
Application number
DK91912759.7T
Other languages
Danish (da)
English (en)
Inventor
Keith Johnson Randall
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24173248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0536282(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK0536282T3 publication Critical patent/DK0536282T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91912759.7T 1990-06-27 1991-06-21 Fremgangsmåde til behandling af prostataadenocarcinom hos mennesker DK0536282T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/544,709 US5300294A (en) 1990-06-27 1990-06-27 Method of treating prostatic adenocarcinoma

Publications (1)

Publication Number Publication Date
DK0536282T3 true DK0536282T3 (da) 1997-10-27

Family

ID=24173248

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91912759.7T DK0536282T3 (da) 1990-06-27 1991-06-21 Fremgangsmåde til behandling af prostataadenocarcinom hos mennesker

Country Status (15)

Country Link
US (2) US5300294A (ja)
EP (1) EP0536282B1 (ja)
JP (5) JP2702280B2 (ja)
KR (1) KR100209825B1 (ja)
AT (1) ATE151635T1 (ja)
AU (1) AU650033B2 (ja)
CA (1) CA2084775C (ja)
DE (1) DE69125714T2 (ja)
DK (1) DK0536282T3 (ja)
ES (1) ES2100952T3 (ja)
GR (1) GR3024064T3 (ja)
HK (1) HK1006412A1 (ja)
IE (1) IE81134B1 (ja)
WO (1) WO1992000010A1 (ja)
ZA (1) ZA914919B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5239075A (en) * 1991-08-21 1993-08-24 Eli Lilly And Company Process for the preparation of benzo (f) quinolinones
CA2084799C (en) 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
US5710275A (en) * 1992-05-20 1998-01-20 Merck & Co., Inc. 7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
EP0641209A4 (en) * 1992-05-20 1995-08-23 Merck & Co Inc NEW 17-ESTER, AMID AND KETONE DERIVATIVES OF 3-OXO-4-AZASTEROIDS AS 5-ALPHA REDUCTINE INHIBITORS.
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9213901D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
CN1133005A (zh) * 1993-09-03 1996-10-09 史密丝克莱恩比彻姆公司 稳定的片剂
US5578724A (en) * 1994-09-20 1996-11-26 Eli Lilly And Company Process for preparation of benzo[f]quinolinones
US5763490A (en) * 1994-09-20 1998-06-09 University Of South Carolina Treating prostate cancer with tartrate ions
US5629007A (en) * 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5635197A (en) * 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
JPH09172979A (ja) * 1995-12-27 1997-07-08 Ajinomoto Co Inc 新規リン酸アミノ酸複合塩及び制酸剤を含有する反すう動物用飼料添加組成物
US6093722A (en) 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
GB9717444D0 (en) * 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US6365181B1 (en) 2000-04-20 2002-04-02 Gattefosse Corporation Thixatropic gelatin carrier composition
CA2554025A1 (en) * 2004-01-28 2005-08-11 Androscience Corporation Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
KR101563370B1 (ko) * 2007-01-08 2015-10-26 앤드로사이언스 코포레이션 (치환된 페닐)-프로페날 잔기를 갖는 화합물, 이의 유도체, 생물학적 활성, 및 이의 용도
MX2010001125A (es) 2007-07-31 2010-09-30 Androscience Corp Composiciones incluyendo receptor androgeno de degradacion (ard) ponteciadores y metodos de tratamiento profilactico o terapeutico de trastornos de la piel y la caida de cabello.
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
MX2015012274A (es) 2013-03-14 2016-06-02 Univ Maryland Agentes de sub-regulacion del receptor de androgeno y uso de los mismos.
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
US10585101B2 (en) 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
JPS63203625A (ja) * 1987-02-19 1988-08-23 Kao Corp ５α−リダクタ−ゼ阻害剤
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US5041433A (en) * 1987-04-29 1991-08-20 Smithkline Beecham Corporation 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4970205A (en) * 1988-12-23 1990-11-13 Smithkline Beecham Corporation Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
ATE230994T1 (de) * 1989-07-07 2003-02-15 Endorech Inc Methode zur behandlung androgenbedingter krankheiten
CA2023157A1 (en) * 1989-08-21 1991-02-22 Gary H. Rasmusson 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma

Also Published As

Publication number Publication date
KR100209825B1 (ko) 1999-07-15
WO1992000010A1 (en) 1992-01-09
IE912233A1 (en) 1992-01-01
DE69125714T2 (de) 1997-10-23
JP2702280B2 (ja) 1998-01-21
CA2084775C (en) 2003-04-15
IE81134B1 (en) 2000-03-22
KR930701175A (ko) 1993-06-11
DE69125714D1 (de) 1997-05-22
US5496556A (en) 1996-03-05
EP0536282A1 (en) 1993-04-14
JP2002308776A (ja) 2002-10-23
ATE151635T1 (de) 1997-05-15
EP0536282B1 (en) 1997-04-16
JP2007063296A (ja) 2007-03-15
EP0536282A4 (en) 1993-05-05
HK1006412A1 (en) 1999-02-26
US5300294A (en) 1994-04-05
CA2084775A1 (en) 1991-12-28
JPH1081625A (ja) 1998-03-31
ES2100952T3 (es) 1997-07-01
GR3024064T3 (en) 1997-10-31
ZA914919B (en) 1992-07-29
AU8207691A (en) 1992-01-23
AU650033B2 (en) 1994-06-09
JPH05508155A (ja) 1993-11-18
JP2000309536A (ja) 2000-11-07

Similar Documents

Publication Publication Date Title
DK0536282T3 (da) Fremgangsmåde til behandling af prostataadenocarcinom hos mennesker
DK1203770T3 (da) Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme
DE69516866D1 (de) Stereochemische wortmanninderivate
FI961697A (fi) 16-substituoidut-4-atsa-androstaani 5alfa-reduktaasi-isotsyymi-1-inhibiittorit
DE69230857D1 (de) Steroid-Sulfatase hemmende Verbindungen
BR9807674A (pt) Inibidores bicìclicos da proteìna farnesil transferase
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
DK0981341T3 (da) Anvendelse af betulinsyrederivater til behandling og forebyggelse af melanom
NO933970L (no) Injeksjon av dekstriner for underjordiske mikrobielle prosesser
DK0463664T3 (da) Fremgangsmåde til behandling af en underjordisk formation
NO934746D0 (no) Injeksjon av organiske fosfater for underjordiske mikrobielle pro sesser
NO910884L (no) Utstyr for fjernstyrt innsetting av sementeringsplugger iundervannsborete broenner.
DE69417925D1 (de) 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
NO911999L (no) Anvendelse av substituerte beta-hydroksyetylaminer som potente hemmestoffer til exoenzymer i sopp.
NO940862D0 (no) Neurotensinfremgangsmåte for inhibering av vaskulær lekkasje
NO965497L (no) Fremgangsmåte for kontrollert fiksering av avleiringsinhibitor i en underjordisk formasjon
NO912782D0 (no) Fremgangsmaate for behandling av skrap av legeringer av sjeldne jordmetaller/overgangsmetaller.
DK0588873T3 (da) Behandling af levercancer
JPS51150116A (en) Repair technique for an undergro und hollow body
JPS51111580A (en) Valve lock system for oilhydraulic system,etc.
SE9100950L (sv) Vvs-armatur foer tvaettstaell
SE8402957D0 (sv) Formstag till gjutveggsformar
DK0864032T3 (da) Fremgangsmåde til behandling af en underjordisk formation
YU12295A (sh) 16-supstituisani-4-aza-androstani inhibitori 5-alfa-reduktaze izozima 1
SE8402505L (sv) Anordning for utstyrningsbegrensning av en manoverventil